{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:33:56Z","timestamp":1790508836830,"version":"4.1.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":4086,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/j.bbmt.2003.09.014","type":"journal-article","created":{"date-parts":[[2004,1,29]],"date-time":"2004-01-29T05:14:39Z","timestamp":1075353279000},"page":"73-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["A new era of antifungal therapy"],"prefix":"10.1016","volume":"10","author":[{"given":"John R","family":"Wingard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Leather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2003.09.014_BIB1","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1086\/344058","article-title":"Antifungal resistance in pathogenic fungi","volume":"35","author":"Perea","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1128\/AAC.18.1.158","article-title":"Incidence of polyene-resistant yeasts recovered from clinical specimens","volume":"18","author":"Dick","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/313748","article-title":"Introduction to antifungal drugs","volume":"30","author":"Dismukes","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.322.7286.579","article-title":"Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours","volume":"322","author":"Eriksson","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1086\/368312","article-title":"Continuous infusion of escalated doses of amphotericin B deoxycholate","volume":"36","author":"Imhof","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB7","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1086\/368317","article-title":"Amphotericin B deoxycholate administered by continuous infusion","volume":"36","author":"Hiemenz","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/319211","article-title":"Mortality and costs of acute renal failure associated with amphotericin B therapy","volume":"32","author":"Bates","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB9","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","article-title":"Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis","volume":"29","author":"Wingard","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB10","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0002-9343(01)00928-7","article-title":"The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy","volume":"111","author":"Harbarth","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB11","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.2000.18.12.2476","article-title":"Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients","volume":"18","author":"Cagnoni","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ki.1991.214","article-title":"Effect of salt supplementation on amphotericin B nephrotoxicity","volume":"40","author":"Llanos","year":"1991","journal-title":"Kidney Int"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1128\/AAC.10.3.555","article-title":"Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys","volume":"10","author":"Bullock","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/infdis\/140.4.564","article-title":"Dopamine and saralasin antagonism of renal vasoconstriction and oliguria caused by amphotericin B in dogs","volume":"140","author":"Reiner","year":"1979","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB15","first-page":"713","article-title":"An experimental model of amphotericin B nephrotoxicity with renal tubular acidosis","volume":"78","author":"Gouge","year":"1971","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB16","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1128\/AAC.42.12.3103","article-title":"Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients","volume":"42","author":"Camp","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/jcp.41.5.494","article-title":"Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients","volume":"41","author":"Smith","year":"1988","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B","volume":"27","author":"Wong-Beringer","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"10.1016\/j.bbmt.2003.09.014_BIB19","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B","volume":"22","author":"Hiemenz","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0149-2918(03)80125-X","article-title":"A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations","volume":"25","author":"Barrett","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB21","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1517\/14656566.4.8.1277","article-title":"The lipid formulations of amphotericin B","volume":"4","author":"Herbrecht","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1358\/dot.1996.32.5.379050","article-title":"Amphotericin B lipid complex","volume":"32","author":"Dix","year":"1996","journal-title":"Drugs Today"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1086\/342563","article-title":"Lipid formulations of amphotericins","volume":"35","author":"Wingard","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-137-2-200207160-00008","article-title":"Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS","volume":"137","author":"Johnson","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB27","series-title":"Programs and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"489","article-title":"Randomized double-blind trial of AmBiosome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients","author":"Hamill","year":"1999"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB28","series-title":"Programs and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"330","article-title":"Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis","author":"Anaissie","year":"1995"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB29","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/10428190109097650","article-title":"Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia","volume":"40","author":"Fleming","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB34","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB35","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB36","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/374553","article-title":"Triad of acute infusion-related reactions associated with liposomal amphotericin B","volume":"36","author":"Roden","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB37","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","article-title":"An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis","volume":"27","author":"Ellis","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0966-842X(94)90618-1","article-title":"Molecular mechanisms of drug resistance in fungi","volume":"2","author":"Vanden Bossche","year":"1994","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB39","doi-asserted-by":"crossref","DOI":"10.1086\/380796","article-title":"Guidelines for treatment of candidiasis","author":"Pappas","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB40","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/AAC.44.3.747-751.2000","article-title":"Bloodstream infections due to Candida species","volume":"44","author":"Pfaller","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB41","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0140-6736(02)08162-X","article-title":"Antifungal drug resistance of pathogenic fungi","volume":"359","author":"Kontoyiannis","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB42","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJM199110313251814","article-title":"Fluconazole and Candida krusei fungemia","volume":"325","author":"Persons","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB43","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.37.9.1847","article-title":"Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients","volume":"37","author":"Wingard","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB44","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1056\/NEJM199110313251803","article-title":"Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole","volume":"325","author":"Wingard","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF01726360","article-title":"Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group","volume":"16","author":"Phillips","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB46","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB47","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/clinids\/12.6.1147","article-title":"Antifungal and surgical treatment of invasive aspergillosis","volume":"12","author":"Denning","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes","volume":"79","author":"Patterson","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB49","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0149-2918(03)80126-1","article-title":"Voriconazole","volume":"25","author":"Jeu","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB50","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0732-8893(02)00507-2","article-title":"In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus species","volume":"45","author":"Serrano","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1185\/030079903125001884","article-title":"Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole","volume":"19","author":"Ullmann","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB53","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1345\/aph.1C261","article-title":"Voriconazole","volume":"37","author":"Pearson","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB54","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB55","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB56","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10096-003-0934-2","article-title":"Two cases of cerebral aspergillosis successfully treated with voriconazole","volume":"22","author":"de Lastours","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB57","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/14656566.4.5.807","article-title":"Caspofungin","volume":"4","author":"Johnson","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"suppl 3","key":"10.1016\/j.bbmt.2003.09.014_BIB58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1439-0507.2002.tb04771.x","article-title":"The first echinocandin","volume":"45","author":"Cornely","year":"2002","journal-title":"Mycoses"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB59","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1056\/NEJMe020142","article-title":"Echinocandins\u2014an advance in the primary treatment of invasive candidiasis","volume":"347","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB60","series-title":"Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17\u201320","article-title":"Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, AMB lipid formulations or azoles","author":"Maertens","year":"2000"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB61","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","article-title":"A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis","volume":"113","author":"Villanueva","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB62","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB63","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.47.4.1376-1381.2003","article-title":"In vitro antifungal activity of micafungin (FK463) against dimorphic fungi","volume":"47","author":"Nakai","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB64","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1128\/AAC.42.9.2299","article-title":"Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus","volume":"42","author":"Vora","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB65","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/jac\/dkf198","article-title":"Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum","volume":"50","author":"Gil-Lamaignere","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB66","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1128\/AAC.46.7.2234-2237.2002","article-title":"Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum","volume":"46","author":"Gil-Lamaignere","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0732-8893(00)00236-4","article-title":"The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus","volume":"39","author":"Chiller","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB68","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1128\/AAC.46.6.1974-1976.2002","article-title":"Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus","volume":"46","author":"Roilides","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB69","series-title":"Combined effects of amphotericin B formulations and azoles on human neutrophil (PMN)-induced damage to hyphae of Aspergillus fumigatus and Aspergillus nidulans. 40th Interscience Conference Antimicrob Agents Chemother. Toronto, Canada","author":"Akpogheneta","year":"2000"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB70","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.1997.15.8.2954","article-title":"Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia","volume":"15","author":"Ohno","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB71","first-page":"107","article-title":"Combined effect of interferon-gamma and voriconazole on neutrophil-induced hyphal damage of Aspergillus fumigatus. 40th Annual Meeting of the Infectious Diseases Society of America (IDSA), Chicago, IL","author":"Winn","year":"2002"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/02681219680000101","article-title":"Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae","volume":"34","author":"Roilides","year":"1996","journal-title":"J Med Vet Mycol"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB73","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1128\/iai.61.11.4870-4877.1993","article-title":"Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon","volume":"61","author":"Roilides","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB74","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1128\/iai.61.4.1185-1193.1993","article-title":"Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon","volume":"61","author":"Roilides","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/cyto.2001.0889","article-title":"Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus","volume":"15","author":"Gonzalez","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB76","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood.V95.11.3302.010k35_3302_3309","article-title":"Phase I\/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation","volume":"95","author":"Price","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB77","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1365-2141.1999.01619.x","article-title":"Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients","volume":"106","author":"Peters","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB78","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/sj.leu.2400811","article-title":"Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions","volume":"11","author":"Dignani","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB79","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00001432-200108000-00004","article-title":"Antifungal prophylaxis in hematopoietic stem cell transplant recipients","volume":"14","author":"Marr","year":"2001","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB80","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM200201243460410","article-title":"Empirical antifungal therapy\u2014new options, new tradeoffs","volume":"346","author":"Marr","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB81","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00001432-200208000-00003","article-title":"Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients","volume":"15","author":"Leather","year":"2002","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB82","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1086\/340263","article-title":"Antifungal chemoprophylaxis after blood and marrow transplantation","volume":"34","author":"Wingard","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB83","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1086\/313756","article-title":"Practice guidelines for diseases caused by Aspergillus","volume":"30","author":"Stevens","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB84","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","article-title":"A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects","volume":"36","author":"Rex","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB85","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9343(89)90441-5","article-title":"Empiric antifungal therapy in febrile granulocytopenic patients","volume":"86","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB87","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7326\/0003-4819-135-6-200109180-00010","article-title":"Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial","volume":"135","author":"Boogaerts","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB88","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB89","series-title":"Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"477","article-title":"A randomized double-blind, multicenter trial of caspofungin (CAS) v liposomal amphotericin B (LAMB) for empirical antifungal therapy (EAFRx) of persistently febrile neutropenic (PFN) patients (Pt)","author":"Walsh","year":"2003"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB90","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0002-9343(88)80343-7","article-title":"An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis","volume":"85","author":"Karp","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB91","first-page":"577","article-title":"Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients","volume":"12","author":"Tollemar","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB92","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/infdis\/165.5.891","article-title":"Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients","volume":"165","author":"Perfect","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB93","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bmt.1702233","article-title":"Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation","volume":"25","author":"Wolff","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB94","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB95","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/515128","article-title":"Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients","volume":"28","author":"Rotstein","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB96","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB97","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB98","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0002-9343(01)01127-5","article-title":"Fluconazole to prevent yeast infections in bone marrow transplantation patients","volume":"112","author":"MacMillan","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB99","first-page":"1","article-title":"Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients\u2014recommendations of the CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation","volume":"49","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB100","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-138-9-200305060-00006","article-title":"Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial","volume":"138","author":"Winston","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB101","article-title":"Itraconazole vs fluconazole for antifungal prophylaxis in allogeneic HSCT recipients","author":"Marr","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB102","series-title":"Randomized, double-blind trial of micafungin (MI) versus fluconazole (FL) for prophylaxis of invasive fungal infections in patients (pts) undergoing hematopoietic stem cell transplant (HSCT), NIAID\/BAMSG Protocol 46. 42nd ICAAC","author":"Van Burik","year":"2002"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB103","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/clinids\/20.6.1535","article-title":"Epidemiology of fungal infections","volume":"20","author":"Pfaller","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB104","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1086\/501967","article-title":"Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction","volume":"23","author":"Raad","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB105","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1001\/archinte.162.13.1483","article-title":"The hospital water supply as a source of nosocomial infections","volume":"162","author":"Anaissie","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB106","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1182\/blood-2002-02-0530","article-title":"Pathogenic molds (including Aspergillus species) in hospital water distribution systems","volume":"101","author":"Anaissie","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB107","doi-asserted-by":"crossref","first-page":"E86","DOI":"10.1086\/342305","article-title":"Cleaning patient shower facilities","volume":"35","author":"Anaissie","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB108","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1086\/338715","article-title":"All catheter-related candidemia is not the same","volume":"34","author":"Walsh","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB109","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/338714","article-title":"Should vascular catheters be removed from all patients with candidemia? An evidence-based review","volume":"34","author":"Nucci","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","article-title":"Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia","volume":"19","author":"Caillot","year":"2001","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bbmt.2003.09.014_BIB111","first-page":"786a","article-title":"Utility of galactomannan detection for the diagnosis of invasive aspergillosis in HSCT recipients","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB112","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood.V97.6.1604","article-title":"Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients","volume":"97","author":"Maertens","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB113","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2002.07.004","article-title":"Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients","volume":"20","author":"Herbrecht","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB114","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1620\/tjem.190.119","article-title":"Rapid, sensitive and simple detection of candida deep mycosis by amplification of 18S ribosomal RNA gene; comparison with assay of serum beta-D-glucan level in clinical samples","volume":"190","author":"Sakai","year":"2000","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB115","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1086\/322631","article-title":"Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer","volume":"33","author":"Lin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB116","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jac\/dkg242","article-title":"Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus","volume":"51","author":"Manavathu","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB117","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/AAC.46.1.245-247.2002","article-title":"In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp","volume":"46","author":"Arikan","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB118","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1128\/AAC.46.9.3039-3041.2002","article-title":"In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp","volume":"46","author":"Perea","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB119","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.46.8.2564-2568.2002","article-title":"Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis","volume":"46","author":"Kirkpatrick","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB120","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1128\/AAC.47.4.1452-1455.2003","article-title":"Efficacy of micafungin alone or in combination against systemic murine aspergillosis","volume":"47","author":"Luque","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB121","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1086\/375420","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis","volume":"187","author":"Petraitis","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB122","series-title":"Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"387","article-title":"Pathological findings in a murine pulmonary aspergillosis model","author":"Nakajima","year":"2000"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB123","series-title":"Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"388","article-title":"Synergistic effects of combination of FK463 with amphotericin B","author":"Kohno","year":"2000"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB124","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cncr.11115","article-title":"Refractory aspergillus pneumonia in patients with acute leukemia","volume":"97","author":"Aliff","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB125","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cncr.11479","article-title":"Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies","volume":"98","author":"Kontoyiannis","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB126","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1086\/375418","article-title":"Combination therapy for aspergillosis","volume":"187","author":"Wheat","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB127","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1439-0507.1991.tb00660.x","article-title":"Combination therapy in a model of pulmonary aspergillosis","volume":"34","author":"Schmitt","year":"1991","journal-title":"Mycoses"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1439-0507.1993.tb00732.x","article-title":"Amphotericin B refractory aspergillosis after itraconazole","volume":"36","author":"Schaffner","year":"1993","journal-title":"Mycoses"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB129","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000238524","article-title":"Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice","volume":"33","author":"Polak","year":"1987","journal-title":"Chemotherapy"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB130","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1128\/AAC.38.12.2843","article-title":"Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus","volume":"38","author":"Maesaki","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2003.09.014_BIB131","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1128\/AAC.46.10.3208-3214.2002","article-title":"Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis","volume":"46","author":"Lewis","year":"2002","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879103003665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879103003665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:57:26Z","timestamp":1761055046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879103003665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":131,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S1083879103003665"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2003.09.014","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new era of antifungal therapy","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2003.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}